公开(公告)号：US08779107B2

公开(公告)日：2014-07-15

申请号：US13125332

申请日：2009-10-19

Applicant: Joseph Altin ,  Ines Atmosukarto ,  Rudolf Maria De Wildt ,  Christopher Parish ,  Jason Price

Inventor： Joseph Altin ,  Ines Atmosukarto ,  Rudolf Maria De Wildt ,  Christopher Parish ,  Jason Price

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K9/127

CPC classification number: A61K39/3955 ,  A61K38/217 ,  A61K39/0011 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/6018 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2317/22 ,  C07K2317/569

Abstract: The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.

Abstract translation: 本公开涉及用于靶向树突状细胞的组合物。 特别地，本公开涉及一种组合物，其包含：a）一种或多种抗原; b）抗DC-SIGN免疫球蛋白单可变区; 和c）承载a）和b）的载体。 本公开还涉及包含这种抗DC-SIGN分子的制剂，组合物和装置及其作为药物的用途，以及用于治疗癌症，适当地为黑素瘤。

公开(公告)号：US20140341971A1

公开(公告)日：2014-11-20

申请号：US14159791

申请日：2014-06-20

Applicant: Joseph ALTIN ,  Ines Atmosukarto ,  Rudolf Maria De Wildt ,  Christopher Parish ,  Jason Price

Inventor： Joseph ALTIN ,  Ines Atmosukarto ,  Rudolf Maria De Wildt ,  Christopher Parish ,  Jason Price

IPC: A61K39/395 ,  A61K39/00 ,  A61K38/21

CPC classification number: A61K39/3955 ,  A61K38/217 ,  A61K39/0011 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/6018 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2317/22 ,  C07K2317/569

Abstract: The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.

Abstract translation: 本发明涉及用于靶向树突状细胞的组合物。 特别地，本发明涉及一种组合物，其包含：a）一种或多种抗原; b）抗DC-SIGN免疫球蛋白单可变区; 和c）承载a）和b）的载体。 本发明还涉及包含这种抗DC-SIGN分子的制剂，组合物和装置及其作为药物的用途，以及用于治疗癌症，适当地为黑素瘤。

公开(公告)号：US20110212168A1

公开(公告)日：2011-09-01

申请号：US13125332

申请日：2009-10-19

Applicant: Joseph Altin ,  Ines Atmosukarto ,  Rudolf Maria De Wildt ,  Christopher Parish ,  Jason Price

Inventor： Joseph Altin ,  Ines Atmosukarto ,  Rudolf Maria De Wildt ,  Christopher Parish ,  Jason Price

IPC: A61K9/127 ,  A61K39/395 ,  A61K38/21 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K38/217 ,  A61K39/0011 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/6018 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2317/22 ,  C07K2317/569

Abstract: The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.

Abstract translation: 本公开涉及用于靶向树突状细胞的组合物。 特别地，本公开涉及一种组合物，其包含：a）一种或多种抗原; b）抗DC-SIGN免疫球蛋白单可变区; 和c）承载a）和b）的载体。 本公开还涉及包含这种抗DC-SIGN分子的制剂，组合物和装置及其作为药物的用途，以及用于治疗癌症，适当地为黑素瘤。

公开(公告)号：US20080038281A1

公开(公告)日：2008-02-14

申请号：US11688621

申请日：2007-03-20

Applicant: Joseph Altin ,  Christopher Parish

Inventor： Joseph Altin ,  Christopher Parish

IPC: A61K39/00 ,  A61P43/00

CPC classification number: A61K38/1866 ,  A61K9/1271 ,  A61K39/0011 ,  A61K47/6911 ,  A61K2039/5152 ,  A61K2039/55555 ,  C12N11/02 ,  G01N33/5432 ,  G01N33/54353 ,  G01N33/92

Abstract: The present invention relates generally to modifying biological and/or synthetic membranes or liposomes, or combinations thereof, for the purpose of altering immunity, or for the targeting of drugs and other agents to a specific cell type or tissue when administered in vivo to achieve a therapeutic effect. Modification of the membranes is achieved by incorporation and/or attachment of metal chelating groups, thereby allowing engraftment of one or more targeting molecules possessing a metal affinity tag, and a targeting of the engrafted membranes to specific cell types or tissues in vivo. The invention, thus, provides a means of modifying the properties of biological and/or synthetic membranes and liposomes for the purpose of altering or enhancing immunity when used as vaccines, or for the targeting of encapsulated/incorporated drugs or other agents to a specific cell type or tissue when administered in vivo, to achieve a therapeutic effect or response, or for modifying a physiological response or biological function.

Abstract translation: 本发明一般涉及改变生物和/或合成的膜或脂质体或其组合，以改变免疫力，或者当在体内施用时将药物和其它试剂靶向特定的细胞类型或组织以实现 治疗效果。 通过掺入和/或附着金属螯合基团来实现膜的修饰，从而允许植入具有金属亲和标签的一种或多种靶向分子，并将植入的膜靶向体内特定的细胞类型或组织。 因此，本发明提供了当用作疫苗时改变生物和/或合成膜和脂质体的性质以改变或增强免疫的目的，或将包封/掺入的药物或其它试剂靶向特定细胞的方法 类型或组织，以实现治疗效果或反应，或用于改变生理反应或生物学功能。

公开(公告)号：US20070026057A1

公开(公告)日：2007-02-01

申请号：US10568939

申请日：2004-08-23

Applicant: Joseph Altin ,  Christopher Parish

Inventor： Joseph Altin ,  Christopher Parish

IPC: A61K39/395 ,  A61K39/02 ,  A61K39/00 ,  A61K9/127 ,  A61K38/20 ,  A61K38/19 ,  A61K38/21

CPC classification number: A61K39/395 ,  A61K9/127 ,  A61K31/4172 ,  A61K38/217 ,  A61K39/00 ,  A61K39/0002 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/04 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55555 ,  A61K2039/55572

Abstract: The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.

Abstract translation: 本发明提供了一种用于通过体内靶向抗原至树突状细胞来调节免疫的组合物。 该组合物包括：含有抗原的膜囊泡或含抗原的脂质体的制备物，其表面上具有多个金属螯合基团; 和在树突状细胞上的受体的配体，该配体通过配体上的金属亲和标签与金属螯合基团连接。 组合物还包括免疫调节因子。 还提供了制备该组合物的方法。 本发明还提供了调节免疫疾病的方法，以及治疗肿瘤和感染的方法。

公开(公告)号：US20050003358A1

公开(公告)日：2005-01-06

申请号：US10485667

申请日：2002-08-05

Applicant: Christopher Parish ,  Vivian Cabalda-Crane

Inventor： Christopher Parish ,  Vivian Cabalda-Crane

IPC: G01N27/62 ,  B01J20/283 ,  C07K7/08 ,  C07K14/47 ,  C12Q1/68 ,  G01N27/64 ,  G01N30/26 ,  G01N30/72 ,  G01N30/88 ,  G01N33/483 ,  G01N33/574 ,  G01N33/68

CPC classification number: G01N33/6848 ,  G01N30/7233 ,  G01N33/574 ,  G01N33/57484 ,  G01N33/57488 ,  G01N33/6851 ,  G01N2405/06

Abstract: Provided are novel cancer markers for the diagnosis of cancer in humans and non-human mammalian subjects, specifically a cancer marker comprising a negatively-charged molecule with a mass/charge (m/z) ratio of about 991. The cancer marker of the invention may be used to determine the presence of one or more cancerous cells or tumors in a biological sample by assaying the sample for a reduced level of said cancer marker.

Abstract translation: 本发明提供了用于人和非人哺乳动物受试者中癌症诊断的新型癌症标志物，特别是包含质量/电荷（m / z）比为约991的带负电荷的分子的癌症标志物。本发明的癌症标志物 可用于通过测定样品以降低水平的所述癌症标志物来确定生物样品中一种或多种癌细胞或肿瘤的存在。